Flubromazepam
Flubromazepam is a designer benzodiazepine with an exceptionally long half-life, first synthesised in 1960 but never developed clinically. A single dose can produce measurable effects and impairment for days. Sold as a research chemical, its very slow elimination makes accumulation, prolonged sedation, dependence and additive respiratory depression with opioids or alcohol its defining hazards.
01 Overview
Flubromazepam re-emerged on the research-chemical market around 2013. A self-experiment case study using a 4 mg oral dose detected the parent compound in blood for more than 11 days, with a terminal half-life estimated at over 100 hours. This is far longer than almost any clinically used benzodiazepine.
The practical consequence is that effects and impairment outlast the user's awareness of them, and repeated dosing causes rapid accumulation to hazardous levels. It also produces active metabolites, further extending duration. Human data are limited to a few pharmacokinetic and forensic reports; there are no controlled clinical trials.
02 Mechanism
Positive allosteric modulator at the GABA-A benzodiazepine site; extremely slow clearance and active metabolites produce a very prolonged effect.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 2–4 mg | Oral | Effects build slowly over many hours. |
| Common | 4–8 mg | Oral | A single dose can impair for several days; do not redose daily. |
| Strong | 8–12 mg | Oral | Heavy, prolonged sedation with marked accumulation risk. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| AnxiolysisLong-lasting reduction of anxiety. | strong and prolonged | Anecdotal | |
| SedationDrowsiness and impaired coordination lasting well beyond a day. | dose-dependent, prolonged | Anecdotal | |
| Muscle relaxationReduced muscle tone. | moderate | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Accumulation and prolonged impairmentThe very long half-life causes drug to accumulate across doses, producing days of unexpected impairment. | Severe | Near-universal with repeat dosing | Observational | |
| Dependence and protracted withdrawalDependence develops; withdrawal is prolonged and can include seizures. | Severe | Common with regular use | Observational | |
| Additive respiratory depressionFatal respiratory suppression possible with opioids or alcohol, compounded by accumulation. | Life-threatening | Uncommon but potentially fatal | Observational |